Drug Trial Radar · NCT07462780
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Mar 5, 2026
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a first-in-human (FIH) trial of CMS-D017 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple ascending dose (MAD) study (referred to as Part 2 MAD). The study aims to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of CMS-D017 capsules following single and multiple oral administrations in healthy Chinese adult participants. Both parts of the study are designed as randomized, double-blind, placebo-controlled, sequential cohort trials. Part 1 SAD plans to include 6 dose cohorts, with 8 participants per cohort (6 receiving CMS-D017 and 2 receiving placebo), for a total of 48 participants. Part 2 MAD plans to include 4 dose cohorts, with 10 participants per cohort (8 receiving CMS-D017 and 2 receiving placebo), for a total of 40 participants.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria, PNH
- Complement-mediated Kidney Disease
Interventions
CMS-D017 CapsuleDrug
healthy participant
CMS-D017 Placebo CapsuleDrug
healthy participant
CMS-D017 CapsuleDrug
healthy subject
CMS-D017 Placebo CapsuleDrug
healthy subject
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of CMS-D017 -Adverse eventsTime frame: Up to 23 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.